Product Description
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sequella
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Philippines, South Africa, Tanzania
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Tuberculosis, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Gates MRI-TBD06-201 | P2 |
Active, not recruiting |
Tuberculosis, Pulmonary |
2025-01-31 |
|
| SUDOCU | P2 |
Completed |
Tuberculosis, Pulmonary |
2022-09-30 |